Wide Moat S&P Global’s Valuation Is Fair

I last reviewed S&P Global (SPGI) in this April 30, 2025 post at which time the current share price was ~$492 and the most current quarterly financial information was for Q1 2025. My suggestion was that investors acquire shares in great companies during periods of turmoil. Now that SPGI has released Q2 and FY2025 results [...]

By |August 1st, 2025|Equity Investing|Comments Off on Wide Moat S&P Global’s Valuation Is Fair

FFJ Portfolio – July 2025

This FFJ Portfolio - July 2025 report is a high-level recap of my activity during the month. In an environment where much does not make sense, it is worthwhile to be prudent. In my FFJ Portfolio - June 2025 report, I note investor willingness to borrow for investment purposes (Debit Balances in Customers' Securities Margin [...]

By |July 31st, 2025|FFJ Portfolio Holdings|Comments Off on FFJ Portfolio – July 2025

Intact Financial Exposure Increased In The FFJ Portfolio

Despite being a loyal Canadian, I have very little desire to invest in Canadian companies. My reasoning is that I think I can generate superior long-term total investment returns from US companies. Secondly, most Canadian listed companies do not satisfy my risk tolerance. This is why I have made a conscious decision to limit my [...]

By |July 30th, 2025|Equity Investing|Comments Off on Intact Financial Exposure Increased In The FFJ Portfolio

Increased Accenture Exposure In The FFJ Portfolio

In my June 27, 2025 Why I Added Accenture To The FFJ Portfolio post, I disclose a new Accenture (ACN) position. Following my initial purchase, I have increased my exposure in keeping with the Final Thoughts expressed in my prior post. ACN is a new holding and my current exposure is only 200 shares. It [...]

By |July 29th, 2025|Equity Investing|Comments Off on Increased Accenture Exposure In The FFJ Portfolio

CME Group – Market Volatility Drives Record Results

I last reviewed CME Group Inc. (CME) in this April 26, 2025 post at which time the Q1 2025 results were the most current. With the release of the Q2 2025 financial results on July 23, 2025, I revisit this existing holding. Business Overview CME operates a derivatives marketplace which offers a range of futures [...]

By |July 26th, 2025|Equity Investing|Comments Off on CME Group – Market Volatility Drives Record Results

Nasdaq Achieves Deleveraging Target Sooner Than Anticipated

On June 12, 2023, Nasdaq (NDAQ) announced its intent to acquire Adenza from Thoma Bravo for ~$10.5B in cash and stock. When making this announcement, it made deleveraging a capital allocation priority. In my June 13, 2023 post, in which I disclose a new NDAQ position, I state: I do not like the degree of [...]

By |July 26th, 2025|Equity Investing|Comments Off on Nasdaq Achieves Deleveraging Target Sooner Than Anticipated

West Pharmaceutical Recovery Continues As Outlook Is Raised Again

I last reviewed West Pharmaceutical (WST) in this July 27, 2024 post in which my Final Thoughts included: I am looking to increase my exposure in great companies that appear to have fallen out of favor. WST certainly falls in this group! WST's business remains fundamentally sound and it is still the industry leader. Despite [...]

By |July 25th, 2025|Equity Investing|Comments Off on West Pharmaceutical Recovery Continues As Outlook Is Raised Again

Thermo Fisher Share Price Surge Is Disappointing

Thermo Fisher's (TMO) share price surge is disappointing for investors wishing to acquire grossly undervalued shares in this high quality company. In recent TMO posts with the most recent being that on July 7, 2025, I suggest that negative investor sentiment presents an investment opportunity. Following the July 23, 2025 Q2 and YTD2025 earnings release, [...]

By |July 24th, 2025|Equity Investing|Comments Off on Thermo Fisher Share Price Surge Is Disappointing

Intuitive Surgical Should Grow Into Its Valuation

I last reviewed Intuitive Surgical (ISRG) in this June 10, 2025 post at which time the most currently available financial information was for Q1 2025. With the recent release of Q2 and YTD2025 results, I revisit this existing holding. Business Overview The Overview section commencing on page 26 of 58 in the Q2 2025 Form [...]

By |July 24th, 2025|Equity Investing|Comments Off on Intuitive Surgical Should Grow Into Its Valuation

Danaher Remains Undervalued

I last reviewed Danaher Corporation (DHR) in this April 25, 2025 post at which time the most current financial information was for Q1 2025. On July 21, 2025, I acquired an additional 100 shares @ $188.30 in a 'Core' account in the FFJ Portfolio bringing my exposure to 901 shares. As I finalize this post [...]

By |July 23rd, 2025|Equity Investing|Comments Off on Danaher Remains Undervalued
Go to Top